Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.73 - $3.2 $8,823 - $16,320
5,100 Added 83.61%
11,200 $20,000
Q1 2024

May 15, 2024

BUY
$1.74 - $3.16 $348 - $632
200 Added 3.39%
6,100 $15,000
Q4 2023

Feb 14, 2024

BUY
$1.42 - $1.96 $6,958 - $9,604
4,900 Added 490.0%
5,900 $10,000
Q3 2023

Nov 14, 2023

SELL
$1.42 - $1.84 $9,798 - $12,696
-6,900 Reduced 87.34%
1,000 $1,000
Q2 2023

Aug 14, 2023

BUY
$1.51 - $2.27 $2,114 - $3,178
1,400 Added 21.54%
7,900 $12,000
Q1 2023

May 15, 2023

SELL
$1.85 - $2.71 $6,660 - $9,756
-3,600 Reduced 35.64%
6,500 $13,000
Q4 2022

Feb 14, 2023

SELL
$1.55 - $2.38 $102,145 - $156,842
-65,900 Reduced 86.71%
10,100 $20,000
Q3 2022

Nov 14, 2022

BUY
$1.75 - $2.62 $2,100 - $3,144
1,200 Added 1.6%
76,000 $137,000

Others Institutions Holding STXS

About Stereotaxis, Inc.


  • Ticker STXS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 74,790,096
  • Market Cap $162M
  • Description
  • Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by pr...
More about STXS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.